The affordable medicines facility-malaria—A success in peril

Abstract The Affordable Medicines Facility-malaria (AMFm) has put into place a bold financing plan for artemisinin-combination therapy in a pilot phase in seven countries covering half the population at risk of malaria in Africa. A report of the AMFm independent evaluation, conducted by ICF Internat...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Talisuna Ambrose O, Adibaku Seraphine, Amojah Chioma N, Amofah George K, Aubyn Vivian, Dodoo Alex, Juma Elizabeth, Jackou Djermakoye H, Mkude Sigsbert, Okui Albert P, Ramarosandratana Benjamin, Shija Shija J
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2012
Subjects:
Malaria/economics
Malaria/treatment
AMFm
ACT
Global fund
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/1475-2875-11-370
https://doaj.org/article/d44028a7b51e4fb1a72312b5418e19ed
Description
Summary:Abstract The Affordable Medicines Facility-malaria (AMFm) has put into place a bold financing plan for artemisinin-combination therapy in a pilot phase in seven countries covering half the population at risk of malaria in Africa. A report of the AMFm independent evaluation, conducted by ICF International and the London School of Hygiene and Tropical Medicine, describes the success of the programme in the pilot sites: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda, comparing availability and affordability of high-quality artemisinin-combination therapies before and after AMFm launched. Proof of concept was achieved: AMFm increased availability and kept prices low, meeting its initial, ambitious benchmarks in most settings. Despite this overwhelming success, opposition to the programme and dwindling resources for malaria control conspire to cripple or kill AMFm.

Similar Items